Salvage therapy with amprenavir and ritonavir: prospective study in 17 heavily pretreated patients.

abstract：OBJECTIVES:ARTEMIS demonstrated significantly greater efficacy of once-daily darunavir/ritonavir (DRV/r) 800/100 mg versus lopinavir/ritonavir 800/200 mg (total daily dose) in treatment-naïve, HIV-1-infected patients at week 96. The influence of baseline characteristics on efficacy and safety was analyzed in DRV/r pati...

journal_title：HIV clinical trials

authors： Fourie J,Flamm J,Rodriguez-French A,Kilby D,Domingo P,Lazzarin A,Ballesteros J,Sosa N,Van De Casteele T,DeMasi R,Spinosa-Guzman S,Lavreys L

更新日期：2011-11-01 00:00:00

abstract：BACKGROUND:The success of longitudinal trials depends greatly on using effective strategies to retain participants and ensure internal validity, maintain sufficient statistical power, and provide for the generalizability of study results. OBJECTIVE:This paper describes the challenges and specific strategies used to re...

journal_title：HIV clinical trials

authors： Wynne J,Muwawu R,Mubiru MC,Kamira B,Kemigisha D,Nakyanzi T,Kabwigu S,Nakabiito C,Kiweewa Matovu F

更新日期：2018-10-01 00:00:00

abstract：PURPOSE:The objective was to evaluate the impact of an intervention for improving adherence to antiretroviral therapies (HAART) in HIV-infected patients. METHOD:We designed a prospective, controlled, randomized trial to assess the impact of an educational and counseling intervention in addition to standard of care. At...

journal_title：HIV clinical trials

authors： Pradier C,Bentz L,Spire B,Tourette-Turgis C,Morin M,Souville M,Rebillon M,Fuzibet JG,Pesce A,Dellamonica P,Moatti JP

更新日期：2003-03-01 00:00:00

abstract：METHOD:Analysis of virological, immunological, and clinical data over 24 weeks of treatment of drug-experienced patients administered didanosine (ddI) and tenofovir (TDF) plus either PI or NNRTI (17 patients) compared to 14 patients on ddI plus lamivudine and to 19 patients on ddI plus stavudine. RESULTS:Patients trea...

journal_title：HIV clinical trials

authors： Di Biagio A,Beltrame A,Cenderello G,Ferrea G,De Maria A

更新日期：2006-01-01 00:00:00

abstract：BACKGROUND:Endothelial progenitor cells (EPCs) are bone marrow-derived cells that contribute to vascular repair. EPCs may be reduced in HIV-infected (HIV+) persons, contributing to cardiovascular disease (CVD). Telmisartan is an angiotensin receptor blocker that increases EPCs in HIV-uninfected adults. OBJECTIVE:To as...

journal_title：HIV clinical trials

authors： Lake JE,Seang S,Kelesidis T,Currier JS,Yang OO

更新日期：2016-11-01 00:00:00

abstract：BACKGROUND:To improve the dosing frequency and pill burden of antiretroviral therapy, we compared two once-daily dosed regimens to a twice-daily dosed regimen. METHOD:HIV-1-infected, antiretroviral drug-naïve adults were randomized to either twice-daily nelfinavir and stavudine and once-daily didanosine (regimen A) or...

journal_title：HIV clinical trials

authors： Lowe SH,Wensing AM,Hassink EA,ten Kate RW,Richter C,Schreij G,Koopmans PP,Juttmann JR,van der Tweel I,Lange JM,Borleffs JC

更新日期：2005-09-01 00:00:00

abstract：UNLABELLED:Patients with prior virologic failure (VF) are at an increased risk of subsequent failure, emergence of resistance, and death. This analysis identifies outcomes and correlates of VF in a high-risk population. METHODS:A5251 was designed to evaluate an enhanced adherence counseling intervention delivered by n...

journal_title：HIV clinical trials

authors： Robbins GK,Cohn SE,Harrison LJ,Smeaton L,Moran L,Rusin D,Dehlinger M,Flynn T,Lammert S,Wu AW,Safren SA,Reynolds NR

更新日期：2016-07-01 00:00:00

abstract：PURPOSE:Previous studies with intermittent interleukin-2 (IL-2) therapy using intermediate and high levels of IL-2 have demonstrated significant increases in the CD4 + T cell count in HIV-infected patients. Intermittent regimens are amenable to outpatient use, but severe adverse events are frequently experienced with i...

journal_title：HIV clinical trials

authors： Lalezari JP,Beal JA,Ruane PJ,Cohen CJ,Jacobson EL,Sundin D,Leong WP,Raffanti SP,Wheeler DA,Anderson RD,Keiser P,Schrader SR,Goodgame JC,Steinhart CR,Murphy RL,Wolin MJ,Smith KA

更新日期：2000-11-01 00:00:00

abstract：PURPOSE:To investigate the factors that contribute to willingness to participate in HIV clinical trials and to determine the impact of a brief intervention on willingness to participate. METHODS:115 consecutive outpatients receiving HIV primary care participated in this prospective study. Each patient completed a ques...

journal_title：HIV clinical trials

authors： Volkmann ER,Claiborne D,Currier JS

更新日期：2009-03-01 00:00:00

abstract：OBJECTIVES:Statins are lipid-lowering drugs that exhibit anti-Inflammatory and immune-modulatory properties, leading to a reduction of serum levels of C-reactive protein (CRP) in the general population. DESIGN:To assess the anti-inflammatory effects of statins in HIV-infected patients, because very limited data are av...

journal_title：HIV clinical trials

authors： Calza L,Vanino E,Salvadori C,Manfredi R,Colangeli V,Cascavilla A,Di Bari MA,Motta R,Viale P

更新日期：2014-01-01 00:00:00

abstract：BACKGROUND:Simple antiretroviral drug combinations might provide a comparable benefit to standard triple regimens in patients with mild HIV disease, because poor adherence and toxicities often compromise the sustained benefit of the latest triple regimens, especially when protease inhibitors are used. Bad adherence is ...

journal_title：HIV clinical trials

authors： de Mendoza C,Ramos JT,Ciria L,Fortuny C,García FJ,de José MI,Asensi F,Soriano V

更新日期：2002-01-01 00:00:00

abstract：PURPOSE:To assess the virologic and immunologic response to a boosted double-protease inhibitor (PI) regimen of highly pretreated patients infected with HIV-1 and to examine the role of PI resistance and concentration of serum saquinavir. METHOD:In an open-label prospective study, lopinavir/ritonavir, saquinavir-sgc, ...

journal_title：HIV clinical trials

authors： Smith GH,Boulassel MR,Klien M,Gilmore N,MacLeod J,LeBlanc R,René P,Routy JP,Lalonde RG

更新日期：2005-03-01 00:00:00

abstract：PURPOSE:We obtained peripheral blood monocytes from HIV-1-infected patients and differentiated them into macrophages in vitro to investigate the contribution of purified monocytes to plasma viremia in HIV-infected patients. METHOD:We compared the production of HIV-1 from purified monocytes isolated from patients who w...

journal_title：HIV clinical trials

authors： Kazanjian P,Adams D,Tate S,Newman G

更新日期：2002-11-01 00:00:00

abstract：PURPOSE:We investigated the evolution of serum lipid levels in HIV-infected pregnant women and the potential effect of antiretroviral treatment during pregnancy using data from a national surveillance study. METHOD:Fasting lipid measurements collected during routine care in pregnancy were used, analyzing longitudinal ...

journal_title：HIV clinical trials

authors： Floridia M,Tamburrini E,Ravizza M,Tibaldi C,Ravagni Probizer MF,Anzidei G,Sansone M,Mori F,Rubino E,Meli M,Dalzero S,Guaraldi G,Italian Group on Surveillance on Antiretroviral Treatment in Pregnancy.

更新日期：2006-07-01 00:00:00

abstract：PURPOSE:Treatment options for HIV-associated lipodystrophy syndrome (HALS) remain limited. The objective of this randomized open-label study was to compare three emerging therapies, rosiglitazone, pravastatin, and growth hormone alone and together, in men and women with HALS. METHOD:Sixty-four subjects received daily ...

journal_title：HIV clinical trials

authors： Macallan DC,Baldwin C,Mandalia S,Pandol-Kaljevic V,Higgins N,Grundy A,Moyle GJ

更新日期：2008-07-01 00:00:00

abstract：PURPOSE:Selecting the optimal treatment regimen for antiviral-naive patients may be difficult, given the concern about the antiviral activity, the development of drug resistance, and the increase in drug costs. This study evaluates the costs and effectiveness of using lopinavir/ritonavir (LPV/r) vs. nelfinavir (NFV), b...

journal_title：HIV clinical trials

authors： Simpson KN,Luo MP,Chumney E,Sun E,Brun S,Ashraf T

更新日期：2004-09-01 00:00:00

abstract：BACKGROUND:Raltegravir (RAL) constitutes the first available integrase strand transfer inhibitor (INSTI) available in clinical practice. Three independent pathways have been described to confer resistance to RAL. Secondary mutations with little effect on INSTI susceptibility and additional substitutions with an uncerta...

journal_title：HIV clinical trials

authors： Gutiérrez C,Hernández-Novoa B,Pérez-Elías MJ,Moreno AM,Holguín A,Dronda F,Casado JL,Moreno S

更新日期：2013-01-01 00:00:00

abstract：OBJECTIVES:Despite substantial improvements in HIV outcomes with combination antiretroviral therapy (cART), morbidity and mortality remain above population norms. The gut mucosal immune system is not completely restored by cART, and the resultant microbial translocation may contribute to chronic inflammation, inadequat...

journal_title：HIV clinical trials

authors： Kim CJ,Walmsley SL,Raboud JM,Kovacs C,Coburn B,Rousseau R,Reinhard R,Rosenes R,Kaul R

更新日期：2016-07-01 00:00:00

abstract：BACKGROUND:Multiple resistance to nucleoside analogs mediated by the Q151M complex and/or codon 67-69 inserts/deletions represents a growing problem among HIV-infected persons, most of whom have been exposed to sequential therapies for long periods of time. PATIENTS AND METHOD:All plasma samples collected from HIV-inf...

journal_title：HIV clinical trials

authors： Gallego O,d Mendoza C,Labarga P,Altisent C,González J,García-Alcalde I,Valer L,Valencia E,Soriano V

更新日期：2003-11-01 00:00:00

abstract：:This article reports noteworthy HIV/AIDS clinical trials presented at the XVth International AIDS Conference, Bangkok, July 2004, and also outlines goals of comprehensive prevention, care, treatment, and monitoring plans. The Bangkok conference theme was "Access for All." Outlined are goals of comprehensive prevention...

journal_title：HIV clinical trials

authors： Idemyor V

更新日期：2005-01-01 00:00:00

abstract：BACKGROUND:A safe, effective, easy-to-dose antiretroviral therapy that minimizes hepatic complication risk is essential in optimizing HIV-HCV treatment. Nucleoside-sparing boosted protease inhibitor monotherapy may achieve this goal. METHODS:A prospective, open-label pilot simplification study of once-daily lopinavir/...

journal_title：HIV clinical trials

authors： Cooper C,la Porte C,Tossonian H,Sampalis J,Ackad N,Conway B

更新日期：2012-07-01 00:00:00

abstract：OBJECTIVE:To determine the prevalence of CCR5-tropic HIV-1 among treatment-experienced patients in Spain. DESIGN:Epidemiologic, cross-sectional, and non-interventional study between January and June 2008 in HIV-1-infected patients in Spain. METHODS:A total of 485 treatment-experienced patients from across Spainand wi...

journal_title：HIV clinical trials

authors： Moreno,Clotet,Sarría,Ortega,Leal,Rodriguez-Arrondo,Sánchez-de la Rosa,Allegro Study Group.

更新日期：2009-11-01 00:00:00

abstract：PURPOSE:A comprehensive study comparing the costs and efficacies of darunavir/ritonavir 800/100 mg qd and the other ritonavir-boosted (/r) protease inhibitors (PIs) recommended for treatment-naïve individuals with HIV-1 infection would help health care decision makers identify the value of each boosted PI. METHODS:A c...

journal_title：HIV clinical trials

authors： Brogan AJ,Mrus J,Hill A,Sawyer AW,Smets E

更新日期：2010-05-01 00:00:00

abstract：BACKGROUND:Nevirapine, a nonnucleoside analogue, has demonstrated suppression of human immunodeficiency virus (HIV) replication alone and in combination therapy. However, the durable suppression of HIV with nevirapine when used along with other nucleosides in HIV-infected patients who are treated in clinical practice n...

journal_title：HIV clinical trials

authors： Allan PS,Arumainayagam J,Harindra V,Tobin J,Browning M,Yoganathan K,Wade A,Das S

更新日期：2003-07-01 00:00:00

abstract：PURPOSE:Questionnaires assessing patient-reported outcomes in HIV are either too long or not HIV-specific. Our aim was to develop and validate a simplified HIV patient questionnaire. METHOD:607 HIV patients treated with a combination of antiretroviral (ARV) drugs were enrolled in an observational, longitudinal study. ...

journal_title：HIV clinical trials

authors： Spire B,Arnould B,Barbier F,Durant J,Gilquin J,Landman R,Carret S,Saussier C,El Kebir S,Cohen-Codar I

更新日期：2009-07-01 00:00:00

abstract：:Naturally occurring polymorphisms at positions involved in resistance to antiretroviral agents are frequently seen in HIV-1 non-B subtypes. Although they do not seem to affect significantly the susceptibility to antiretroviral drugs in vitro, they may facilitate the selection of different pathways and/or a more rapid ...

journal_title：HIV clinical trials

authors： Holguín A,Soriano V

更新日期：2002-09-01 00:00:00

abstract：BACKGROUND:We hypothesized that nitazoxanide (NTZ) added to pegylated interferon alfa-2a (PEG-IFN) and weight-based ribavirin (WBR) would improve hepatitis C virus (HCV) virologic responses in HCV treatment-naïve HIV-1/HCV genotype 1 coinfected persons. METHODS:Prospective, single-arm study in which subjects received ...

journal_title：HIV clinical trials

authors： Amorosa VK,Luetkemeyer A,Kang M,Johnson VA,Umbleja T,Haas DW,Yesmin S,Bardin MC,Chung RT,Alston-Smith B,Tebas P,Peters MG

更新日期：2013-11-01 00:00:00

abstract：BACKGROUND:In recent ritonavir-boosted protease inhibitor (PI) studies, high efficacy rates have been observed, with few PI mutations detected. METHOD:To better understand the types of mutations observed and their phenotypic impact and the likelihood of virologic failure (VF) on a regimen that includes either a ritona...

journal_title：HIV clinical trials

authors： Ross L,Vavro C,Wine B,Liao Q

更新日期：2006-11-01 00:00:00

abstract：BACKGROUND:The lack of human resources for health is presently recognized as a major factor limiting scale-up of antiretroviral treatment (ART) programs in resourcelimited settings. The mobilization of public and private partners, the decentralization of care, and the training of non-HIV specialist nurses and general p...

journal_title：HIV clinical trials

authors： Clevenbergh P,Van der Borght SF,van Cranenburgh K,Janssens V,Kitenge Lubangi C,Gahimbaza L,Lange JM,Rinke de Wit TF,Rijckborst H

更新日期：2006-09-01 00:00:00

abstract：OBJECTIVE:To describe baseline and emergent HIV-1 resistance to elvitegravir/ cobicistat/emtricitabine/tenofovir DF (EVG/COBI/FTC/TDF) and ritonavir-boosted atazanavir/emtricitabine/tenofovir DF (ATV+RTV+FTC/TDF) in HIV-1-infected, treatment-naïve subjects through 144 weeks. METHOD:This was a randomized, double-blind,...

journal_title：HIV clinical trials

authors： Kulkarni R,Abram ME,McColl DJ,Barnes T,Fordyce MW,Szwarcberg J,Cheng AK,Miller MD,White KL

更新日期：2014-09-01 00:00:00